Haleos Labs Limited (HALEOSLABS) is currently trading at 1,497.20 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

SMS Lifesciences India Limited is primarily involved in the manufacturing and export of Active Pharmaceutical Ingredients (APIs) and their intermediates. The company operates multiple facilities across Hyderabad. Originally incorporated as a real estate private limited company in 2006, SMS Lifesciences has undergone several transformations, including demergers and acquisitions. The company holds significant recognition as an export house since 1997, indicating expertise in global pharmaceutical supply chains. With three multi-product facilities and a research center, SMS Lifesciences engages in contract manufacturing and research assignments for an international clientele. A strategic demerger in 2017 positioned the company to leverage semi-regulated units, enhancing its manufacturing capabilities and international market reach.

Over the past 52 weeks, Haleos Labs Limited has traded between a low of ₹1,100.60 and a high of ₹1,778.35. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Haleos Labs Limited has a market capitalization of approximately 438.38. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Haleos Labs Limited’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 28.73 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 438.38 Cr, Haleos Labs Limited is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Haleos Labs Limited operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Haleos Labs Limited is 28.73. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.

Consolidated net sales were ₹72.94 crore in Q1 FY27, down 11.59% year-on-year from ₹82.50 crore in Q1 FY26.